Cara Therapeutics Initiates Human Abuse Liability Trial of CR845 Comparator will be pentazocine, a Schedule IV opioid receptor agonist with lower abuse potential than common opioids Top-line data expected in fourth quarter of 2014 SHELTON, Conn., July...

Cara Therapeutics Earns Milestone Payment From Maruishi Pharmaceutical for Completion of Phase 1 Clinical Trial of I.V. CR845 in Japan SHELTON, Conn., July 16, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...

Cara Therapeutics Announces Appointment of Robert Medve, M.D., as Chief Medical Officer SHELTON, Conn., June 24, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...

Cara Therapeutics Initiates Phase Ia/Ib Trial of Tablet Formulation of Oral CR845 for the Treatment of Acute and Chronic Pain SHELTON, Conn., June 18, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...

Cara Therapeutics Names Eric J. Vandal Vice President, Commercial Operations SHELTON, Conn., June 2, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...